Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABR-215050

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Tasquinimod (ABR‐215050) is an orally active quinoline‐3‐carboxamide analog that inhibits occurrence of experimental metastasis… Expand
2013
2013
Purpose: The novel anti-tumor agent tasquinimod (ABR-215050) is being developed for treatment of metastatic castration-resistant… Expand
Highly Cited
2012
Highly Cited
2012
Tasquinimod (ABR‐215050) is an orally active quinoline‐3‐carboxamide analog that has completed phase II clinical trial in… Expand
Highly Cited
2012
Highly Cited
2012
By breeding TRAMP mice with S100A9 knock-out (S100A9−/−) animals and scoring the appearance of palpable tumors we observed a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Tasquinimod (ABR-215050) is an oral drug in clinical development for treatment of patients with castrate resistant prostate… Expand
Highly Cited
2009
Highly Cited
2009
BackgroundThe orally active quinoline-3-carboxamide tasquinimod [ABR-215050; CAS number 254964-60-8), which currently is in a… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
2007
2007
15510 Background: Preclinical studies have demonstrated that ABR-215050, an orally active 3-quinoline-carboxamide derivative with… Expand
Highly Cited
2006
Highly Cited
2006
Linomide, Figure 1, produces robust and consistent in vivo growth inhibition of prostate cancer models via its anti‐angiogenic… Expand